Terns is now a wholly-owned subsidiary of Merck and its stock will no longer be listed or traded on the Nasdaq Global Select ...
Merck has FDA approval for a new combination drug for HIV, giving patients a new treatment option and an alternative to a blockbuster Gilead Sciences pill that comes with tolerability and side effect ...
Merck MRK is scheduled to report third-quarter 2025 results on Oct. 30. Investors are likely to focus on the sales performance of its blockbuster cancer drug, Keytruda. The drug accounted for more ...
Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of ...
Robert F. Kennedy Jr. and a group of personal injury lawyers have long accused Merck & Co. of “disease mongering” to boost ...
Add Yahoo as a preferred source to see more of our stories on Google. A wall showing a Merck & Co. logo in Kenilworth, New Jersey (Courtesy of Merck & Co.) This story was originally published on ...
Mounjaro surpasses Keytruda top sales with $8.7B in Q1 2025, marking a 125% increase for Eli Lilly over Merck's cancer drug.
Add Yahoo as a preferred source to see more of our stories on Google. Illustration shows Merck logo (Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the ...
Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that ...
By Sabrina Valle NEW YORK, April 22 (Reuters) - Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co, ...
Merck & Co. scientists use a suite of enzymes to manufacture the cholesterol-lowering drug candidate enlicitide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results